Manelimab is a humanized monoclonal antibody fusion protein (immunocytokine) targeting the human interleukin-10 receptor alpha subunit (IL-10Ra). IL-10Ra is a critical component of the anti-inflammatory IL-10 signaling pathway. Manelimab specifically binds to and activates the IL-10Ra receptor, mimicking the biological functions of IL-10 and inducing the phosphorylation of the downstream JAK1/STAT3 signaling pathway. This activation significantly inhibits the release of pro-inflammatory cytokines (such as TNF-alpha, IL-1b, and IL-6) and enhances the polarization of immunosuppressive macrophages. This immunocytokine has potential applications in the research of autoimmune diseases, chronic inflammation, and as an immunotherapy to modulate the tumor microenvironment.
CAS Nummer:
[2168561-26-8]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
